Black Diamond Q3 2022 net loss $21.7M; cash $144.2M into Q3 2024

Black Diamond Therapeutics, Inc.

2022-Q3 EPS reported -$1.93

Net loss $21.7M vs $35.1M YoY; R&D expenses fell to $15.8M from $27.6M.
Cash, equivalents & investments $144.2M at Sep 30, 2022, vs $209.8M Dec 31, 2021.
Net cash used in operations $16.5M for Q3 vs $26.5M a year ago; runway through Q3 2024.
BDTX-1535 clinical update expected in 2023; IND for BDTX-4933 planned H1 2023.
Appointed Melanie Morrison as SVP Development Operations in October 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.6

Black Diamond Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Black Diamond Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001701541-22-000034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.